GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AnaptysBio Inc (NAS:ANAB) » Definitions » EBIT per Share

AnaptysBio (AnaptysBio) EBIT per Share : $-5.38 (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is AnaptysBio EBIT per Share?

AnaptysBio's EBIT per Share for the three months ended in Mar. 2024 was $-1.40. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-5.38.

During the past 3 years, the average EBIT per Share Growth Rate was -88.20% per year. During the past 5 years, the average EBIT per Share Growth Rate was -14.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for AnaptysBio's EBIT per Share or its related term are showing as below:

ANAB' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -187.5   Med: -23.3   Max: 15.6
Current: -88.2

During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of AnaptysBio was 15.60% per year. The lowest was -187.50% per year. And the median was -23.30% per year.

ANAB's 3-Year EBIT Growth Rate is ranked worse than
96.09% of 1305 companies
in the Biotechnology industry
Industry Median: 3.4 vs ANAB: -88.20

AnaptysBio's EBIT for the three months ended in Mar. 2024 was $-37.62 Mil.


AnaptysBio EBIT per Share Historical Data

The historical data trend for AnaptysBio's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AnaptysBio EBIT per Share Chart

AnaptysBio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.56 -0.73 -2.05 -3.82 -5.41

AnaptysBio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.43 -1.33 -1.24 -1.40 -1.40

AnaptysBio EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

AnaptysBio's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

EBIT per Share(A: Dec. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=-145.54/26.924
=-5.41

AnaptysBio's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

EBIT per Share(Q: Mar. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=-37.619/26.801
=-1.40

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AnaptysBio  (NAS:ANAB) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.


AnaptysBio EBIT per Share Related Terms

Thank you for viewing the detailed overview of AnaptysBio's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


AnaptysBio (AnaptysBio) Business Description

Traded in Other Exchanges
Address
10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
AnaptysBio Inc is a clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonists. The entity generates revenue from collaborative research and development arrangements.
Executives
Paul F. Lizzul officer: Chief Medical Officer 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Eric J Loumeau officer: General Counsel C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Daniel Faga director 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Dennis Mulroy officer: Chief Financial Officer
John A Orwin director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Rita Jain director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Hamza Suria director, officer: President, CEO C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121
Oleg Nodelman director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Magda Marquet director ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
J. Anthony Ware director C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121
Laura Hamill director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Marco Londei officer: Chief Medical Officer C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121
Dominic Piscitelli officer: Chief Financial Officer C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121
James N Topper director 550 HAMILTON AVENUE, SUITE 100, PALO ALTO CA 94301